Portfolio News: Avillion LLP announced publication of the full positive results from the MANDALA Phase III trial of AstraZeneca 's PT027 in asthma patients in the New England Journal of Medicine. Read more here: lnkd.in/eEfQ9pBm

Portfolio News: Exicure announced a $5 million private placement raise with participation from Abingworth. Proceeds are to support the advancement of preclinical candidates including its SCN9A product candidate, a non-opioid pain analgesic. Read more: bit.ly/3Lm4Pyc

We are proud to announce the initiation of the first-in-human phase 1 clinical study of ADX-097 for the treatment of complement disorders and look forward to continuing our work to develop biologic therapeutics for #autoimmune and #inflammatory diseases: prn.to/3MSSH9J

Portfolio company Launch Therapeutics, formed with backing from Abingworth and The Carlyle Group to offer industry partners innovative models to provide funding and development expertise for late-stage clinical assets has announced its first partnership deal. bit.ly/3PlPZd7

Congratulations to our portfolio company Vaxcyte on its positive data from the Phase 1/2 proof-of-concept study evaluating VAX-24, a 24-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease. investors.vaxcyte.com/news-releases/…

Congratulations to Avillion & AstraZeneca as FDA Advisory Committee recommends PT027 as a new rescue treatment for asthma in adults. bit.ly/3A256nj

We are delighted to announce the appointment of Joy Ghosh as Managing Director. Welcome to the team Joy, great to have you on board! abingworth.com/media/abingwor…

Congratulations to portfolio company Soleno Therapeutics which has announced a financing commitment for up to $60 million from Abingworth, Nantahala Capital Management and Vivo Capital. Read the press release from Soleno Therapeutics here: bit.ly/3W7IJWH

Verona Pharma ($VRNA) is pleased to announce positive #Phase3 data from its ENHANCE-1 trial in #COPD. The trial met the primary and key secondary endpoints demonstrating improvements in lung function, symptoms and quality of life. See more detail here: bit.ly/3WxtDcM

Portfolio company Launch Therapeutics has announced a strategic collaboration with Pathalys Pharma to advance its therapeutic candidate upacicalcet through pivotal phase 3 studies for secondary hyperparathyroidism in dialysis patients. Read the PR: bit.ly/3iPGSHx

Pixium Vision announces #FDA Breakthrough Device Designation for the Prima System in Dry AMD Read the Press Release: pixium-vision.com/2023/03/pixium… #pixium #vision #AMD #DryAMD #medicaldevices #ophthalmology #PRIMA #clinicaltrials #reimbursement #healthcare #innovation #ALPIX #BVS

We are excited to announce a collaboration with Pierre Fabre for the co-development of STX-721 and our newest candidate, STX-241—both potentially best-in-class, highly selective, next gen mutant #EGFR inhibitors for the treatment of #NSCLC. Read more: bit.ly/3nL1l2n

Tim Haines, Executive Partner, will give a keynote speech 'Investment Trends for the Life Sciences Industry' at BioTrinity 2023 on Tuesday 25 April at 9:00 am BST in London, UK. Find out more: bit.ly/40CFEQp

The University Spin-out Investment Terms (USIT) Guide has been published by TenU in collaboration with UK universities and investors, including Abingworth. The guidance aims to accelerate and support the founding of start-ups from higher education. bit.ly/43YtHXj

Kurt von Emster, Managing Partner and Head of Abingworth Life Sciences and Graham Mills, PhD, Investment Manager will participate in panels at Bio€quity Europe 2023 in Dublin, Ireland. View the conference agenda: conferences.biocentury.com/bioequity-euro…

Excited to announce the close of our new Clinical Co-Development Co-Investment Fund (CCD-CIF) at $356 million. The CCD-CIF continues to underpin our commitment to provide capital to partners advancing late-stage product development & bringing innovative medicines to patients

Today Q32 Bio and Homology Medicines announced they have entered into a definitive merger agreement. The combined company will focus on advancing Q32’s wholly owned clinical candidates for #autoimmune and #inflammatorydiseases. Learn more: prn.to/3su6lLA